Founded on the vision of ethically and scientifically exploring the full potential of stem cells for transforming medicine and offering new hope to millions of people, Stempeutics Research Pvt.Ltd. is striving ceaselessly on its path towards developing innovative stem cell products that address prominent unmet medical needs with an ‘India first, global next’ approach.Stempeutics, founded by the Manipal Group in 2006, is a late-stage life science company focused on developing and commercializing novel therapeutics based on adult stem cells.Scientists working at Stempeutics have filed over 65 patents and have published over 75 peer-reviewed international publications.The company’s flagship product, Stempeucel® drug, is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells (MSC) derived from the bone marrow of healthy, adult volunteers.Research conducted at Stempeutics has shown that pooling technology balances out variations observed with individual donor cells, resulting in a product with strong immune-modulatory properties, broader cytokine/growth factors array, longer lifespan, and consistent clinical outcomes.Stempeucel® is being developed for the treatment of Critical Limb Ischemia (CLI), Osteoarthritis (OA), Diabetic Foot Ulcer (DFU), Perianal Fistula (PAF), and Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 pneumonia.In August 2020, the Drug Controller General of India (DCGI) granted the manufacturing and marketing approval of Stempeucel® product for the treatment of CLI.Stempeucel® has strong patent protection with 18 patent applications filed across the globe out of which 16 have been granted.The core Stempeucel® patent has been granted in the USA, Australia, New Zealand, South Africa, Japan, China, Singapore, UK, France, Germany, Italy, and the Philippines.The proprietary technology also helps Stempeucel® extend the therapeutic potential of the drug across multiple disease categories.In Critical Limb Ischemia, Stempeucel® directly addresses the root cause of the disease by reducing inflammation, stimulating the growth of collateral blood vessels, and repairing damaged muscle, thereby reducing the pain, healing the ulcers, and salvaging the affected limb.“Our company strongly believes in ‘Science Driving the Business’.While there are many companies around the world focusing on ‘Mesenchymal Stromal Cells’, the stem-cell technology platform what we have adopted is unique and novel for the development of treatment for immune-mediated and inflammatory diseases,” says Mr. BN Manohar – the MD and CEO of Stempeutics Research.Mr.
Summary - A new market study, Global Oxygen Therapy Market (By Product Type- Oxygen concentrators, Compressed Oxygen Cylinders, Liquid oxygen systems, Hyperbaric Oxygen Therapy Chamber, Oxygen masks & Nasal Cannulas, By Application Type – COPD, Pneumonia, Asthma, Cystic Fibrosis, Acute Respiratory Distress Syndrome, Haemorrhage, Sleep Apnea & Others, By End-Users- Hospitals & Nursing Homes and By Transportability- Portable devices & Stationary devices) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025 ” has been featured on WiseGuyReports.Moreover, scope of home-based treatment solutions for lifestyle corrections and reimbursement policies in many countries have propelled the growth of the market during the forecast period 2017 - 2025.Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.The segmentation also includes by type, by application, end-users and transportability in all regions.The company profiling of the key players on a competitive basis in oxygen therapy market across five broad geographic regions are included in this study.Therefore, the report provides the forecast of the global market for the period from 2017 to 2025; offering an inclusive study of the oxygen therapy market.ALSO READ:  https://icrowdnewswire.com/2021/01/11/global-oxygen-therapy-market-2020-share-trend-segmentation-and-forecast-to-2026/The report provides the size of the oxygen therapy market in 2016 and the forecast for the next eight years up to 2025.Based on, oxygen source type, application, end-users and transportability, we have summed up the individual revenues from all the geographical regions to achieve the global revenue.In the absence of specific data (related to the sales of oxygen therapy of several privately held companies), calculated assumptions have been made in view of the company’s penetration and regional presence.ALSO READ: http://www.marketwatch.com/story/automotive-led-lights-market-2020-global-trends-market-share-industry-size-growth-opportunities-and-market-forecast-to-2026-2021-01-20The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market.
Summary-A new market study,”Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023″ has been featured on WiseGuyReports.Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023Overview: Respiratory diseases are one of the world’s biggest health concerns, causing one-sixth of all deaths worldwide.It is observed that more than 35 million people suffer from some form of the respiratory disorder, and one in six deaths is caused by some kind of chronic lung disease in the US alone.Some of the chronic respiratory diseases are acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, pneumonia, respiratory failure, sleep apnea, lung cancer, tuberculosis, and other respiratory diseases.The devices used for the diagnosis, treatment, and monitoring of these cardiopulmonary disorders are known as respiratory care devices.ALSO READ: https://www.einpresswire.com/article/523295696/respiratory-care-devices-2020-global-industry-size-share-trends-key-players-analysis-applications-forecasts-to-2025The factors such as rising prevalence of respiratory diseases, huge demand for enhanced portable devices, increasing geriatric population, and high prevalence of tobacco smoking are expected to drive the market growth during the forecast period.Smoking causes about 90% of all lung cancer deaths and 80% of all deaths from chronic obstructive pulmonary disease (COPD).A massive undiagnosed sleep apnea population is expected to provide an opportunity for the growth of the respiratory care devices market in the future.ALSO READ: http://www.marketwatch.com/story/medical-enterprise-data-storage-market-growth-opportunities-2021-2027-global-trends-share-revenue-top-key-players-and-more-2021-01-20Market Analysis: The “Global Respiratory Care Devices Market” is estimated to witness a CAGR of 8.8% during the forecast period 2017–2023.
(Ohio State University) An unfortunate truth about using mechanical ventilation to save lives is that the pressure can cause further lung damage. Scientists have identified a helpful molecule produced by immune cells during ventilation and are working to boost that natural process in pursuit of a therapy that could lower the chances for lung damage in patients on vents.
10
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Inhaled Nitric Oxide Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/inhaled-nitric-oxide-market/download-sampleMarket DynamicsThe major drivers strengthening the Inhaled Nitric Oxide Market includes growing respiratory disease such as acute respiratory distress syndrome (ARDS) across the globe.Also, increase in research and development investment in improving inhaled nitric oxide application in the healthcare sector will surely help in driving the demand of inhaled nitric oxide.Moreover, the high demand in the treatment for hypoxemic respiratory failure in newly born infants is positively impacting the market.It is highly effective in enhancing oxygenation in infants with continual pulmonary hypertension of the newborn (PPHN).Due to its selective pulmonary vasodilator effects, INO therapy is majorly used for treating hypoxemic respiratory failure in infants.
Global Acute Respiratory Distress Syndrome Market Trends and Forecast to 2027The Global Acute Respiratory Distress Syndrome Market Report is an extensive and comprehensive document comprising details on business strategies, qualitative and quantitative analysis of the market on global and regional levels.The report strives to offer a deeper understanding of the Acute Respiratory Distress Syndrome industry by offering an extensive overview of the competitive landscape and regional segmentation.The report assesses the impact of various market factors on the growth of the Acute Respiratory Distress Syndrome market in key regions and across key segments.Furthermore, the report provides a comprehensive analysis of the impact of the COVID-19 crisis on the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2089The report provides a panoramic overview of the Acute Respiratory Distress Syndrome market’s competition landscape through a thorough profiling of the companies with regards to their market share, recent developments and advancements, gross margins, business expansion plans, product portfolio, production and manufacturing capacity, financial standing, and revenue contribution.Top Players Covered in the Report Include:Faron Pharmaceuticals, BioMarck Pharmaceuticals, GE Healthcare, Hamilton Medical AG, Smiths Medical, Athersys, GlaxoSmithKline, Altor Bioscience, BPL Technologies, and MondobiotechRequest a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2089Furthermore, the report segments the market on the basis of types, applications, and key geographical regions.Device Type Outlook (Revenue in USD Million; Volume in Tons, 2017–2027)Monitoring DevicesDiagnostic DevicesBlood Gas AnalyzersPulse OximetersSpirometersCapnography DevicesOther Diagnostic DevicesTherapeutic DevicesMechanical VentilatorsInvasive and Non-invasive VentilatorsDrug Delivery DevicesNebulizersHumidifiersPAPOthersInjury Type Outlook (Revenue in USD Million; Volume in Tons, 2017–2027)Brain InjuryLung InjurySeverity Outlook (Revenue in USD Million; Volume in Tons, 2017–2027)MildModerateSevereTreatment Outlook (Revenue in USD Million; Volume in Tons, 2017–2027)Fibro ProliferateExudative StageResolution StageRecovery StageSales Channel Outlook (Revenue in USD Million; 2017–2027)Direct salesChannel salesEnd-User (Revenue in USD Million; 2017–2027)HospitalsClinicsAmbulatory Service CentersOthersRegional Segmentation:The Global Acute Respiratory Distress Syndrome Market is analyzed across the key geographical regions where the market has already established its presence.These regions include key areas such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.Further, each region is extensively analyzed on the country level for the production and consumption ratio, import/export, supply and demand dynamics, trends, developments, revenue contribution, market share in terms of volume and value, and the presence of the prominent players in each region.The extensive analysis of the key geographical regions include:North America (U.S., Canada)Europe (U.K., Italy, Germany, France, Rest of EU)Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)Latin America (Chile, Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)To know more about the report, visit @ https://www.reportsanddata.com/report-detail/acute-respiratory-distress-syndrome-ards-marketKey Points Covered by the Report:The report offers a comprehensive overview of the global Acute Respiratory Distress Syndrome Market along with the idea about the content of the research studyThe report offers strategic recommendations to both established and novice players to aid in fortifying their presenceThe report presents insightful data to the companies to help them gain maximum returns on their investment and formulate new investment strategiesIt provides a comprehensive overview of the competitive landscape to offer a competitive edge to the readersThe report covers an extensive regional analysis to impart a better understanding of the spread of the market in key geographies of the worldIn-depth analysis of the current and emerging market trends and drivers and restraintsAn 8-year comprehensive forecast for the Acute Respiratory Distress Syndrome market on the global and regional scaleThorough SWOT analysis and Porter’s Five Forces analysisBrowse Related Reports –T-Cell Therapy Market Future Growth with Technology and Outlook 2020 to 2027 – https://www.reportsanddata.com/report-detail/t-cell-therapy-marketAllergy Immunotherapy Market 2027: Regional Trend & Growth Projections – https://www.reportsanddata.com/report-detail/allergy-immunotherapy-marketThank you for reading our report.For further information or query regarding the report or its customization, please connect with us.
Summary - A new market study, titled “ Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts…November 26, 2020 Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023Overview: Respiratory diseases are one of the world’s biggest health concerns, causing one-sixth of all deaths worldwide.It is observed that more than 35 million people suffer from some form of the respiratory disorder, and one in six deaths is caused by some kind of chronic lung disease in the US alone.Some of the chronic respiratory diseases are acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, pneumonia, respiratory failure, sleep apnea, lung cancer, tuberculosis, and other respiratory diseases.The market is witnessing the emerging trend of intelligent ventilators, portable PAP devices, smart inhalers, and nebulizers which are helping in providing real-time monitoring and transmission of data to the physicians.The markets in India, Brazil, China, and Japan are expected to grow at a rapid pace during the forecast period as the prevalence of respiratory diseases in these countries is high.The major driver of the respiratory device market is high smoking global population, which is increasing the disease burden.The market is analyzed based on three segments – product types, end-users, and regions.Regional Analysis: The regions covered in the report are the Americas, EMEA, APAC, and Rest of the World (ROW).
Summary - A new market study, titled “Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023” has been featured on WiseGuyReports.It is observed that more than 35 million people suffer from some form of the respiratory disorder, and one in six deaths is caused by some kind of chronic lung disease in the US alone.Some of the chronic respiratory diseases are acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, pneumonia, respiratory failure, sleep apnea, lung cancer, tuberculosis, and other respiratory diseases.The market is witnessing the emerging trend of intelligent ventilators, portable PAP devices, smart inhalers, and nebulizers which are helping in providing real-time monitoring and transmission of data to the physicians.The markets in India, Brazil, China, and Japan are expected to grow at a rapid pace during the forecast period as the prevalence of respiratory diseases in these countries is high.The major driver of the respiratory device market is high smoking global population, which is increasing the disease burden.The market is analyzed based on three segments – product types, end-users, and regions.Regional Analysis: The regions covered in the report are the Americas, EMEA, APAC, and Rest of the World (ROW).
Summary - A new market study, titled “Global Respiratory Care Devices Market Research Report 2020”has been featured on WiseGuy Reports.About Online GamblingGlobal Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023 Overview: Respiratory diseases are one of the world’s biggest health concerns, causing one-sixth of all deaths worldwide.It is observed that more than 35 million people suffer from some form of the respiratory disorder, and one in six deaths is caused by some kind of chronic lung disease in the US alone.Some of the chronic respiratory diseases are acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, pneumonia, respiratory failure, sleep apnea, lung cancer, tuberculosis, and other respiratory diseases.The market is witnessing the emerging trend of intelligent ventilators, portable PAP devices, smart inhalers, and nebulizers which are helping in providing real-time monitoring and transmission of data to the physicians.The markets in India, Brazil, China, and Japan are expected to grow at a rapid pace during the forecast period as the prevalence of respiratory diseases in these countries is high.ALSO READ : https://www.einpresswire.com/article/523295696/respiratory-care-devices-2020-global-industry-size-share-trends-key-players-analysis-applications-forecasts-to-2025Key Players: ResMed, Medtronic Plc, Fisher and Paykel, Becton Dickenson and Company, Hamilton Medical, Drager Healthcare GmbH, Chart Industries, Philips Healthcare, Maquet (Getinge Group), Masimo Corp., GE Healthcare and other predominate & niche players.Competitive Analysis: At present, the therapeutic devices are dominating the Global Respiratory Care Devices market, and a lot of new players are focusing on developing smart devices to provide real-time end to end services and to gain future business opportunities.
Global Portable Oxygen Concentrators Market was valued US$ XX  Mn in 2019 and is expected to reach XX Mn by 2027, at a CAGR of XX % during a forecast period.The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters.The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.A portable oxygen concentrator is used to provide oxygen therapy to the patients.Pulse dose technology is safer and reliable than continuous flow technology.Additionally growing numbers for acute respiratory distress syndrome, occupational lung diseases, infectious diseases, and other chronic disorders are also expected to increase the product demand.North America is projected to share significant growth in the global portable oxygen concentrators market.The growth in the market is attributed to the favorable government initiatives like the presence of the Federal Aviation Administration (FAA), which allow the usage of portable concentrators during air travel.Additionally, the presence of some of the many key players like SeQual, Inogen, Invacare, Oxus, AirSep, Philips Respironics, and Inova Labs Inc., in the region is expected to boom the global portable oxygen concentrators market.Furthermore, Asia Pacific is projected to grow at a XX % rate of CAGR in the global portable oxygen concentrators market during the forecast period.
The Global report entails the overall and all-encompassing study of the Acute Respiratory Distress Syndrome Therapeutics Market with all its relevant factors that might have an influence on the growth of the market.This report is rooted in the methodical quantitative and qualitative evaluation of the global Acute Respiratory Distress Syndrome Therapeutics market.Furthermore, it also evaluates the most recent improvements while estimating the growth of the leading players Therabron Therapeutics Inc., Serendex Pharmaceuticals A/S, Silence Therapeutics Plc, Histocell S.L., Altor BioScience Corporation, Athersys Inc., Faron Pharmaceuticals Oy, FirstString Research Inc., GlaxoSmithKline Plc, Phylogica Limited of the market.The key aim of this Global  report is to provide updates and data relating to the Acute Respiratory Distress Syndrome Therapeutics market and also make out all the opportunities for expansion in the market.The synopsis section comprises market dynamics entailing market restraints, drivers, trends, and opportunities trailed by pricing analysis and value chain analysis.Click Here To Access The Sample Report: https://www.syndicatemarketresearch.com/sample/acute-respiratory-distress-syndrome-therapeutics-marketThe report presents a demand for individual segment in each region.Further, the report provides valuable data such as offerings, revenue, and a business outline of the prominent players in the Acute Respiratory Distress Syndrome Therapeutics market.Every segment expansion is evaluated along with the evaluation of their growth in the forecast period.
Market HighlightsThe global radiofrequency ablation devices market is expected to grow at an approximate CAGR of 11.2% during the forecast period of 2018–2023.Factors such as the advantage of radiofrequency ablation over other ablation medical procedures, the success rate of radiofrequency are driving the growth of the market.Moreover, complications such as acute respiratory distress syndrome where success rates are low and burning sensation at the treatment site of tissue are some of the factors hindering the growth of the market.Request Sample Copyhttps://www.marketresearchfuture.com/sample_request/7634SegmentationThe global radiofrequency ablation devices market is segmented on the basis of type, application, and region.Based on the type, the global radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation.By application, the global radiofrequency ablation devices market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain ManagementRegional AnalysisThe Americas dominates the global market for radiofrequency ablation devices owing to the growing geriatric population, increase in cancer cases, an increase in clinical research within the region.Additionally, the increasing awareness about the cardiology treatment and presence of developed economies and healthcare sector within the region drives the market growth during the forecast period.In 2017, it was estimated that Europe stood second in the global radiofrequency ablation devices market due to the increasing prevalence of gynecology, cosmetology, pain management, and others.
A new market study, titled “Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023 …October 04, 2020Global Respiratory Care Devices Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023 Overview: Respiratory diseases are one of the world’s biggest health concerns, causing one-sixth of all deaths worldwide.It is observed that more than 35 million people suffer from some form of the respiratory disorder, and one in six deaths is caused by some kind of chronic lung disease in the US alone.Some of the chronic respiratory diseases are acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, pneumonia, respiratory failure, sleep apnea, lung cancer, tuberculosis, and other respiratory diseases.The market is witnessing the emerging trend of intelligent ventilators, portable PAP devices, smart inhalers, and nebulizers which are helping in providing real-time monitoring and transmission of data to the physicians.The major driver of the respiratory device market is high smoking global population, which is increasing the disease burden.Regional Analysis: The regions covered in the report are the Americas, EMEA, APAC, and Rest of the World (ROW).
(The Korea Advanced Institute of Science and Technology (KAIST)) KAIST researchers have identified key markers that could help pinpoint patients who are bound to get a severe reaction to COVID-19 infection. This would help doctors provide the right treatments at the right time, potentially saving lives. The findings were published in the journal Frontiers in Immunology on August 28.
This damage may be directly caused by the virus as well as by an immune system thrown off-kilter by the infection.
Today the company Equillium reported that clinical trials of their drug itoizamub “significantly reduced mortality” in patients with COVID-19. Equillium is a clinical-stage biotechnology company whose focus is largely COVID-19-related – like many companies of this sort at the moment. They reported today that a Biocon, India clinical trial with itolizumab “significantly reduced mortality in patients hospitalized with COVID-19.” As … Continue reading
Mechanical ventilation of children in intensive care units is often necessary, but can damage the lungs of critically ill patientsIt's possible to change ventilator settings to reduce the risk of damage without putting child patients at risk, according to engineering researchers at the University of WarwickThey successfully tested their new treatment strategies on simulated patients using data from real patients collected at the Children's Hospital of Philadelphia, published in the journal Intensive Care MedicineChanging the ventilation settings for children on life support can reduce the risk of damage to their lungs, researchers at the University of Warwick and the Children's Hospital of Philadelphia have found on computer simulated patients.Paediatric Acute Respiratory Distress Syndrome (PARDS) is one of the most challenging diseases for doctors to manage in the pediatric intensive care unit, and can arise due to several different causes, such as pneumonia, sepsis, trauma, and drowning.Mechanical ventilation is a life-saving medical intervention for many such patients, but the forces and stresses applied by the ventilator can themselves further damage the lungs (so-called ventilator induced lung injury - VILI).
INDIANAPOLIS -- A patented Indiana University School of Medicine discovery that uses proteins, lipids and nucleic acids secreted by adult stem cells to treat Acute Respiratory Distress Syndrome, or ARDS, has been optioned to Theratome Bio, an Indianapolis-based life sciences company.One of the symptoms of ARDS is a buildup of fluid and severe inflammation in the lungs, which impairs their ability to exchange oxygen and carbon dioxide.More than 200,000 people in the U.S. are affected by ARDS each year, and the mortality rate is approximately 40 percent.The patented IU discovery uses the secretome from the stem cells as a biologic therapeutic to reduce the inflammation and buildup of fluid in the lungs.The IU Innovation and Commercialization Office exclusively optioned the treatment to Theratome Bio, which is building a portfolio of therapeutics based on the secretome of stem cells.Michael Coleman, president and CEO of Theratome Bio, said: "There is no effective pharmacotherapy for ARDS.
NEW YORK (October 22, 2018) - A new artificial intelligence (AI) tool is being built to help doctors better identify and treat a deadly, but underrecognized, form of lung failure.Approximately 200,000 people in the United States suffer from acute respiratory distress syndrome (ARDS), which occurs when the lungs fill with fluid, and organs are deprived of oxygen."By using new technology we hope to help clinicians identify ARDS as early as possible, when treatment may be most effective."To create the screening tool, researchers and data and computer scientists are building off of Montefiore Einstein's existing AI platform, combing through years of de-identified patient data to determine dozens of critical, objective data points for ARDS."We have seen the power of AI and predictive analytics to accurately pinpoint patients at risk for other critical conditions and believe AI can be effective in helping clinicians identify patients with ARDS too," said Parsa Mirhaji, M.D., Ph.D., director of Clinical Research Informatics, director of the Center for Health Data Innovations at Montefiore Einstein and associate professor, Systems and Computational Biology at Albert Einstein College of Medicine."The ultimate goal is for AI to become a standard tool for clinicians, helping them provide the best care for our patients."
This report studies the global market size of Acute Respiratory Distress Syndrome Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Respiratory Distress Syndrome Therapeutics in these regions.This research report categorizes the global Acute Respiratory Distress Syndrome Therapeutics market by players/brands, region, type and application.This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.In 2017, the global Acute Respiratory Distress Syndrome Therapeutics market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018.The objectives of this study are to define, segment, and project the size of the Acute Respiratory Distress Syndrome Therapeutics market based on company, product type, application and key regions.The various contributors involved in the value chain of Acute Respiratory Distress Syndrome Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers.Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/2314117The key manufacturers in the Acute Respiratory Distress Syndrome Therapeutics includeTherabron Therapeutics, Inc.Serendex Pharmaceuticals A/SSilence Therapeutics PlcHistocell S.L.Altor BioScience CorporationAthersys, Inc.Faron Pharmaceuticals OyFirstString Research, Inc.GlaxoSmithKline PlcPhylogica LimitedMarket Size Split by TypeMethylprednisoloneHydrocortisoneCalf Pulmonary Surfactant for InjectionOthersMarket Size Split by ApplicationIn-PatientOut-PatientBrowse the complete report @ http://www.orbisresearch.com/reports/index/global-acute-respiratory-distress-syndrome-therapeutics-market-insights-forecast-to-2025Market size split by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaThe study objectives of this report are:To study and analyze the global Acute Respiratory Distress Syndrome Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.To understand the structure of Acute Respiratory Distress Syndrome Therapeutics market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Acute Respiratory Distress Syndrome Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Acute Respiratory Distress Syndrome Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.To project the value and volume of Acute Respiratory Distress Syndrome Therapeutics submarkets, with respect to key regions (along with their respective key countries).To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.This report includes the estimation of market size for value (million US$) and volume (K Pcs).Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Respiratory Distress Syndrome Therapeutics market, to estimate the size of various other dependent submarkets in the overall market.Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research.All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.For the data information by region, company, type and application, 2017 is considered as the base year.
More

Top